Octaplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

Octaplex is a recombinant coagulation factor that acts within the intrinsic pathway of the clotting cascade to correct specific factor deficiencies.

• Hemophilia B: provides temporary replacement of factor IX to control and prevent bleeding.
• Acquired factor IX deficiency: supplies the missing protein to restore normal clotting function.
• Peri‑operative management: ensures adequate hemostasis during surgery for patients with factor IX deficiency.

• Octaplex contains recombinant human factor IX, which binds to activated factor X on platelet surfaces, forming the intrinsic tenase complex. This complex accelerates the conversion of prothrombin to thrombin, leading to fibrin clot formation and restoration of normal hemostasis in patients lacking functional factor IX.

Adverse reactions to Octaplex are generally related to its protein nature and the intravenous route of administration.

Common Side Effects

• Fever
• Headache
• Nausea
• Mild infusion‑site erythema
• Transient increase of ALT/AST

Serious or Rare Side Effects

• Anaphylactic reaction
• Development of inhibitors (neutralising antibodies) to factor IX
• Thromboembolic events
• Severe hypersensitivity including serum sickness
• Disseminated intravascular coagulation (DIA ).

Octaplex should be used only under the supervision of a qualified healthcare professional familiar with coagulation disorders.

• Dosing individualisation: adjust dose based on patient’s factor IX activity levels and clinical response.
• Monitoring: regularly assess factor IX activity and watch for inhibitor development.
• Contra‑indications: avoid in patients with known hypersensitivity to any component of the product.
• Pregnancy and lactation: use only if clearly needed; benefits must outweigh risks.
• Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplex may interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid)

• Antifibrinolytics (e.g., tranexamic acid) combined with high‑dose factor IX may increase thrombosis risk.
• Immune‑modulating therapies that could accelerate inhibitor formation.

Moderate Interactions (Monitor Closely)

• Concomitant use of other clotting factor concentrates.
• Concurrent anticoagulants (e.g., warfarin, direct oral anticoagulants) requiring careful monitoring of coagulation parameters.
• Vaccines administered shortly before or after infusion may alter immune response.
• Antibiotics such as beta‑lactams that can cause hypersensitivity reactions.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding tendency if factor levels are sub‑therapeutic.